| Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications J Löfblom, J Feldwisch, V Tolmachev, J Carlsson, S Ståhl, FY Frejd FEBS letters 584 (12), 2670-2680, 2010 | 756 | 2010 |
| Tumor imaging using a picomolar affinity HER2 binding affibody molecule A Orlova, M Magnusson, TLJ Eriksson, M Nilsson, B Larsson, ... Cancer research 66 (8), 4339-4348, 2006 | 639 | 2006 |
| Selection and characterization of HER2/neu-binding affibody ligands M Wikman, AC Steffen, E Gunneriusson, V Tolmachev, GP Adams, ... Protein Engineering Design and Selection 17 (5), 455-462, 2004 | 371 | 2004 |
| Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled affibody molecules RP Baum, V Prasad, D Müller, C Schuchardt, A Orlova, A Wennborg, ... Journal of nuclear medicine 51 (6), 892-897, 2010 | 352 | 2010 |
| Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule V Tolmachev, A Orlova, R Pehrson, J Galli, B Baastrup, K Andersson, ... Cancer research 67 (6), 2773-2782, 2007 | 274 | 2007 |
| First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule J Sörensen, D Sandberg, M Sandström, A Wennborg, J Feldwisch, ... Journal of nuclear medicine 55 (5), 730-735, 2014 | 267 | 2014 |
| Measuring HER2-receptor expression in metastatic breast cancer using [68Ga] ABY-025 Affibody PET/CT J Sörensen, I Velikyan, D Sandberg, A Wennborg, J Feldwisch, ... Theranostics 6 (2), 262, 2016 | 252 | 2016 |
| Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors A Orlova, V Tolmachev, R Pehrson, M Lindborg, T Tran, M Sandstrom, ... Cancer research 67 (5), 2178-2186, 2007 | 237 | 2007 |
| Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain JT Andersen, R Pehrson, V Tolmachev, MB Daba, L Abrahmsén, ... Journal of biological chemistry 286 (7), 5234-5241, 2011 | 210 | 2011 |
| Design of an optimized scaffold for affibody molecules J Feldwisch, V Tolmachev, C Lendel, N Herne, A Sjöberg, B Larsson, ... Journal of molecular biology 398 (2), 232-247, 2010 | 203 | 2010 |
| Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule M Friedman, A Orlova, E Johansson, TLJ Eriksson, I Höidén-Guthenberg, ... Journal of molecular biology 376 (5), 1388-1402, 2008 | 198 | 2008 |
| Pretargeted imaging and therapy M Altai, R Membreno, B Cook, V Tolmachev, BM Zeglis Journal of Nuclear Medicine 58 (10), 1553-1559, 2017 | 179 | 2017 |
| Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy V Tolmachev, A Orlova, FY Nilsson, J Feldwisch, A Wennborg, ... Expert opinion on biological therapy 7 (4), 555-568, 2007 | 169 | 2007 |
| Preparation and evaluation of 68Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors I Velikyan, ÅL Sundberg, Ö Lindhe, AU Höglund, O Eriksson, E Werner, ... Journal of nuclear medicine 46 (11), 1881-1888, 2005 | 166 | 2005 |
| On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model A Orlova, H Wållberg, S Stone-Elander, V Tolmachev Journal of Nuclear Medicine 50 (3), 417-425, 2009 | 154 | 2009 |
| Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry V Tolmachev, M Friedman, M Sandström, TLJ Eriksson, D Rosik, M Hodik, ... Journal of Nuclear Medicine 50 (2), 274-283, 2009 | 147 | 2009 |
| Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. FY Nilsson, V Tolmachev Current opinion in drug discovery & development 10 (2), 167-175, 2007 | 145 | 2007 |
| Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected … V Tolmachev, D Rosik, H Wållberg, A Sjöberg, M Sandström, M Hansson, ... European journal of nuclear medicine and molecular imaging 37, 613-622, 2010 | 143 | 2010 |
| Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2: 2395, with C-terminally engineered cysteine S Ahlgren, H Wållberg, TA Tran, C Widström, M Hjertman, L Abrahmsén, ... Journal of Nuclear Medicine 50 (5), 781-789, 2009 | 142 | 2009 |
| 99mTc-maEEE-ZHER2:342, an Affibody Molecule-Based Tracer for the Detection of HER2 Expression in Malignant Tumors T Tran, T Engfeldt, A Orlova, M Sandström, J Feldwisch, L Abrahmsén, ... Bioconjugate chemistry 18 (6), 1956-1964, 2007 | 139 | 2007 |
Anna Orlovaprofessor, Uppsala UniversityVerified email at pet.medchem.uu.se
